Vol 13, No 4 (April 29, 2024): Translational Lung Cancer Research

Original Article

Development and validation of a deep learning-based model to predict response and survival of T790M mutant non-small cell lung cancer patients in early clinical phase trials using electronic medical record and pharmacokinetic data
Ning Lou, Xinge Cui, Xinyuan Lin, Ruyun Gao, Chi Xu, Nan Qiao, Ji Jiang, Lu Wang, Weicong Wang, Shanbo Wang, Wei Shen, Xin Zheng, Xiaohong Han
Translational Lung Cancer Research  
2024;
13
(4)
:706-720
.
CT-based radiomics and clinical characteristics for predicting bone metastasis in lung adenocarcinoma patients
Qiushi Su, Bingyan Wang, Jia Guo, Pei Nie, Wenjian Xu
Translational Lung Cancer Research  
2024;
13
(4)
:721-732
.
Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Nancy Alnassar, Jonathan M. J. Derry, Giuseppe Luigi Banna, Dariusz C. Gorecki
Translational Lung Cancer Research  
2024;
13
(4)
:733-748
.
Effect of histological subtype on the efficacy of perioperative chemotherapy in pulmonary sarcomatoid carcinoma: a retrospective study based on SEER population
Tengyong Wang, Zihuai Wang, Jian Zhou, Zongyuan Li, Hu Liao, Jiandong Mei, Qiang Pu, Lunxu Liu
Translational Lung Cancer Research  
2024;
13
(4)
:749-762
.
Molecular and immune characterization of Chinese early-stage non-squamous non-small cell lung cancer: a multi-omics cohort study
Haoxin Peng, Xiangrong Wu, Xiaoli Cui, Shaopeng Liu, Yueting Liang, Xiuyu Cai, Mengping Shi, Ran Zhong, Caichen Li, Jun Liu, Dongfang Wu, Zhibo Gao, Xu Lu, Haitao Luo, Jianxing He, Wenhua Liang
Translational Lung Cancer Research  
2024;
13
(4)
:763-784
.
Carrying on with life as a lung cancer survivor: a qualitative study of Australian survivors’ employment, finances, relationships, and healthcare experiences
Rebekah Laidsaar-Powell, Phyllis Butow, Bea Brown, Kimberley Mander, Jane Young, Emily Stone, Venessa Chin, Emily Banks, Chloe Yi Shing Lim, Nicole M. Rankin
Translational Lung Cancer Research  
2024;
13
(4)
:785-798
.
Clinicopathological characterization of next-generation sequencing detected mutations in lung cancers—a single-center experience
Julia Walter, Amanda Tufman, Jörg Kumbrink, Jens Neumann, Kathrin Kahnert, Laura Sellmer, Andreas Jung, Jürgen Behr, Diego Kauffmann-Guerrero
Translational Lung Cancer Research  
2024;
13
(4)
:799-810
.
Prolonged survival and novel prognostic factors in women with pleural mesothelioma treated with extended pleurectomy decortication
Moshe Lapidot, Emanuele Mazzola, Raphael Bueno
Translational Lung Cancer Research  
2024;
13
(4)
:811-820
.
Impact of lymph node dissection on cancer-specific survival in non-small cell lung cancer patients: a SEER database analysis
Ziran Zhao, Yibo Gao, Fengwei Tan, Qi Xue, Shugeng Gao, Jie He
Translational Lung Cancer Research  
2024;
13
(4)
:821-838
.
Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis
Gengwei Huo, Ying Song, Xiongwen Chen, Peng Chen
Translational Lung Cancer Research  
2024;
13
(4)
:839-848
.
Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study
Xun Wang, Xin Wang, Bengang Hui, Jingsheng Cai, Heng Zhao, Bowei Qiao, Jiangnan Duan, Kezhong Chen, Jun Wang, Jie Lei, Fan Yang
Translational Lung Cancer Research  
2024;
13
(4)
:849-860
.
Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis
Tian Tian, Yanying Li, Juan Li, Hongyu Xu, Hua Fan, Jiang Zhu, Yongsheng Wang, Feng Peng, Youling Gong, Yijia Du, Xiaoyan Yan, Xiulan He, Ayse Ece Cali Daylan, Andreas Pircher, Shane S. Neibart, Yusuke Okuma, Min Hee Hong, Meijuan Huang, You Lu
Translational Lung Cancer Research  
2024;
13
(4)
:861-874
.
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18
Yuanyuan Zhang, Hao Zeng, Chang Qi, Sihan Tan, Qin Huang, Xin Pu, Kenichi Suda, Mariacarmela Santarpia, Panwen Tian, Yalun Li
Translational Lung Cancer Research  
2024;
13
(4)
:875-884
.
Accurate categorization and rapid pathological diagnosis correction with Micro-Raman technique in human lung adenocarcinoma infiltration level
Bo Dai, Dong Han, Yufei Miao, Yong Zhou, Mohammadreza Hajiarbabi, Yiqing Wang, Christopher J. Butch, Huiming Cai, Jian Hu
Translational Lung Cancer Research  
2024;
13
(4)
:885-900
.
Identifying optimal surgical approach among T1N2–3M0 non-small cell lung cancer patients: a population-based analysis
Tao Ge, Shi-Qi Hu, Jing Ning, Yi-Fei Zhou, Dong-Liang Bian, Mei-Xin Teng, Lin-Song Chen, Jie Yang
Translational Lung Cancer Research  
2024;
13
(4)
:901-929
.

Editorial Commentary

The evolving treatment landscape for BRAF-mutated non-small cell lung cancer
Matthew Dankner, Jennifer Maxwell, April A. N. Rose
Translational Lung Cancer Research  
2024;
13
(4)
:930-935
.
Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?
Toyoaki Hida
Translational Lung Cancer Research  
2024;
13
(4)
:936-939
.
MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations
Jan Trøst Jørgensen, Edyta M. Urbanska, Jens Mollerup
Translational Lung Cancer Research  
2024;
13
(4)
:940-946
.
Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?
Yusuke Inoue
Translational Lung Cancer Research  
2024;
13
(4)
:947-951
.
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinib
Boris Duchemann, Emmanuelle Fabre, Jordi Remon
Translational Lung Cancer Research  
2024;
13
(4)
:952-955
.
Small cell, big promises: targeting small cell lung cancer with CAR T cells
Estela Noguera-Ortega, Steven M. Albelda
Translational Lung Cancer Research  
2024;
13
(4)
:956-960
.